# Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

> **NCT05238220** · — · COMPLETED · sponsor: **Piedmont Healthcare** · enrollment: 37 (actual)

## Conditions studied

- Kidney Transplant; Complications

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT05238220
- **Lead sponsor:** Piedmont Healthcare
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238220, "Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05238220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*